ipilimumab,oxaliplatin,nivolumab
bms
[]
 cm649 3-yr fu shows os benefit in oxali-based chemo + nivo vs. chemo in #1l her2- gastric/gej adenoca. interesting to see that orr is higher w/chemo + nivo irrespective of pd-l1+ subsets on subgroup analysis #gi23 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope